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Human immunodeficiency virus continued to be the greatest challenge and killer disease of the 21st century
despite the advent of potent highly active antiretroviral therapy which are limited by their severe adverse effects,
significant drug interactions, frequent dosing, limited bioavailability, and less access to viral reservoir sites like
macrophages. Nano-medicines are becoming new hopes in avoiding these shortcomings of conventional
antiretroviral drugs. The emphasis of this review is mainly the application of polymers based nanomedicines in
pharmacotherapy of HIV/AIDS. Most of the studies to date on this area are in vitro and human clinical trials are
totally missed. However, many interesting points are uncovered through this review like the possibility of achieving
high intracellular concentration of drugs, very good antiretroviral activity, improved bioavailability, reduced toxicity
and release of the drugs from nanocarriers for long time reducing the need for frequent dosing. Indeed, a lot of
assignments left behind for researchers to overcome the challenges hindering the wider application of
nanomedicines in treatment of HIV/AIDS.
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Nano-medicine is a term implying the application of
nanotechnology (the technology that uses nanosized parti-
cles) for therapy and diagnosis of diseases. Nanoparticles
have improved pharmacokinetics and tissue distribution of
therapeutic agents there by diminishing toxicity by their
preferential accumulation at the target site. In addition,
they improve therapeutic potential of drugs by facilitating
intracellular delivery and prolonging their retention time
either inside the cell or in blood circulation [1,2].
Nanoparticles can be categorized into three groups: Inor-
ganic nanoparticles, solid lipid nanoparticles and polymer
nanoparticles. Inorganic nanoparticles are the generic term
for several nanoparticles such as gold and magnetic nano-
particles. Solid lipid nanoparticles combine the advantages
but avoiding the disadvantages of other colloidal carriers
such as emulsions, liposomes and polymeric microparticles* Correspondence: jimmapharm@gmail.com
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unless otherwise stated.and nanoparticles. Polymer nanoparticles involve various
natural or biocompatible synthetic polymers [1,3,4].
Polymer therapeutics is a family of compounds and
drug delivery technologies that uses water-soluble poly-
mers as a common core component. One of the biggest
advantages of using these polymers in drug delivery is
the capability to manipulate their properties such as mo-
lecular weight, linkers and many more to adapt to the
drug delivery requirements. They can be subdivided into
several groups: polymer drugs, polymeric –protein con-
jugates, polymer drug conjugates, multicomponent polyp
lexes being developed as non-viral vectors, polymer mi-
celles and dendrimers [2,3].
Polymer-protein conjugates using polyethylene glycol
(PEG) called PEGylation as polymer component are cur-
rently the most advanced class of polymer therapeutics.
They are developed to avoid some of the drawbacks of
peptide, protein and antibody-based drugs like a short
half-life, poor stability and solubility, increased clearance
by the reticuloendothelial system (RES) and immunogen-
icity. PEGylation has been employed in treatment of viral
hepatitis as well as different types of malignancies [4,5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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field, where nearly a dozen of polymeric conjugates
advancing to the clinical trial stage. Several advantages
of these technologies are being reported over the corre-
sponding parent drugs by different clinical trials includ-
ing fewer side effects, enhanced therapeutic efficacy,
ease of drug administration, and improved patient com-
pliance. The therapeutic efficacy of these agents is in-
creased primarily through an enhanced permeability and
retention (EPR) effect of long-circulating polymers [5].
Dendrimers are nanostructures obtained from macro-
molecules such as polyamidoamine (PAMAM), and poly-
propyleneimin; and are highly branched with an inner
core. They are unique in that they have series of branches,
multivalences, well defined molecular weight and globular
structure with controlled surface functionality. The pres-
ence of multivalency nature enables the attachment of
several drug molecules, targeting groups and solublising
groups onto their surfaces in a well defined manner. Beside
their use in drug delivery, dendrimers are also pharmaceut-
ically active compounds against some diseases [4,6].
Micelles are formed from amphiphilic surfactants
which spontaneously associate in aqueous medium to
form core (hydrophobic)-shell (hydrophilic) structures
or vesicles. Polymeric micelles are able to reach parts of
the body that are poorly accessible. However, their tar-
geting ability is limited by the low drug loading and low
drug incorporation stability leading to the loaded drug
to be released before getting to the site of action [7,8].
In general, nanomedicines particularly polymer based
drug delivery systems are highly fascinating and hence
attracting the attention of scientists from different cor-
ners of the world. This is especially true for the diagno-
sis, prevention and treatment of intracellular infections
like hepatitis, tuberculosis and HIV/AIDS [9] which can
be considered as a triple plague in developing countries
like Ethiopia. The underlined fact for this is that we can
easily manipulate their properties like molecular weight
to adapt to the drug delivery requirements. This review,
however, focuses on the role of polymer based nanome-
dicines in the prevention and treatment of HIV/AIDS
with the intention of finding out drugs with better effi-
cacy and toxicity profile which can also completely
eradicate the virus from the body.
The complexity of HIV/AIDS as a disease: challenges to
complete eradication of the virus from the body
If left untreated, HIV infection is associated with very
high viral load in the body leading to progressive fall in
immune cells particularly CD4+ T cells. This can be
interrupted by treatment with highly active antiretroviral
therapy (HAART), which should contain at least three
drugs regimens made up of at least two classes of anti-
retroviral agents. However, the great challenge is thatimmediately after initial infection, this virus is able to
establish reservoirs where it escapes from the effect of
drugs and keeps releasing the viral progeny to the blood
as long as the patient lives. This makes it one of the
chronic and lifelong diseases especially with the intro-
duction of HAART. There are two types of viral reser-
voirs within tissues that serve this role. The anatomical
reservoirs; these are tissues inaccessible to optimal
levels of antiviral drugs due to due to the presence of
barriers, such as the blood–brain barrier (BBB), blood-
cerebrospinal fluid barrier, and blood-testes barrier. and
the others are cellular reservoirs; cells in which this
virus remains latent and hence escaping the action of
antivirals due to the presence of efflux proteins such as
P-glycoprotein and multidrug resistance protein on the
cell surface preventing the drugs from attaining thera-
peutic intracellular concentrations [10,11].
Dendritic cells within lymphoid tissue trap a large num-
ber of extracellular virions on their surface to protect virus
from antiretroviral drugs. On top of this, latently infected
CD4+ T cells help the HIV to persist despite the presence
of effective antiretroviral therapy as it is not replicating at
this stage. Last but not least, monocytes/macrophages that
are specifically found in brain, pulmonary alveoli, spleen
and lymph nodes are relatively long-lived cells since HIV
has very low cytopathic effects on them making them a
persistent reservoir of HIV regardless of the presence of
highly active antiretroviral therapy [11-13]. Therefore, it is
the existence of these persistent and stable reservoirs for
the virus that makes it difficult to efficiently eradicate HIV
from the body even with the advent of HAART. This is due
to the fact that these drugs in free form have poor local bio-
availability and low residence time in these reservoirs when
administered systemically [14] highlighting the need for
new drug or delivery system with the potential of averting
these problems so as to achieve a cure from HIV/AIDS.
The need to advance HIV/AIDS clinical therapies
The HIV/AIDS epidemic is one of the major public
health threats especially in sub-Sahara countries. Glo-
bally, about 35.3 million people were living with HIV in
2012 which is an increase from previous years as more
people are receiving the life-saving antiretroviral therapy.
The prevalence of HIV/AIDS continues to increase and
it is expected that over 90 million people will ultimately
be infected in Africa alone. On the other hand, there
were 2.3 million new HIV infections and 1.6 million
AIDS deaths in 2012 globally. In 2012, 9.7 million people
in low- and middle-income countries received antiretro-
viral therapy, representing 61% of all who were eligible
under the 2010 World Health Organization (WHO) HIV
treatment guidelines. However, under the 2013 WHO
guidelines, the HIV treatment coverage in low- and
middle-income countries represented only 34% of the
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apy not only prevents AIDS-related illness and death: it
also has the potential to significantly reduce the risk of
HIV transmission and the spread of tuberculosis. From
1996 to 2012, antiretroviral therapy averted 6.3 million
AIDS-related deaths worldwide, including 5.2 million
deaths in low- and middle-income countries [15].
However, despite the clear advantages of HAART in
management and prevent of HIV, there are several signifi-
cant shortcomings. Significant drug interactions, additional
and or synergistic toxicity as a result of combination, low
adherence rate secondary to pill burden and frequent dos-
ing, and potential for development of drug resistant virus
which is even more difficult to treat. An additional import-
ant issue is that upon discontinuation of treatment or
when resistance develops, even with HAART, the viral load
rebounds in the blood [16]. Lastly, systemically available
drug needs to cross biological barriers for delivery to cellu-
lar and anatomical sites which most currently available
antiretroviral formulations couldn’t. CNS availability of
most anti-retroviral agent is very low due to poor perme-
ability across the blood–brain barrier. The consequence of
these interdependent processes is insufficient concentra-
tions and very short residence time of the anti-retroviral
agents at the cellular and anatomical sites [16,17].Nanotechnology approaches for delivery of antiretroviral
drugs in HIV/AIDS management
Targeted delivery to HIV reservoir sites would be of sig-
nificant benefit because many antiretroviral drugs do not
penetrate these sites optimally which contribute not only
to viral persistence, but also to the development of drug
resistance [18,19].
Li Wan and colleagues had investigated the peritoneal
macrophage up take, pharmacokinetics and biodistribution
of Macrophage-Targeted PEG-fMLF (N-Formyl- Methionyl-
Leucyl-Phenylalanine) nanocarriers for improving HIV
drug delivery. They showed that uptake by macrophages in-
creased many folds, and also accumulation of nanocarriers
into macrophages of liver, kidneys and spleen increased in
similar manner. This implies that by covalent conjugation
of macrophage targeting moiety fMLF to PEG, it is possible
to achieve a higher accumulation in macrophages residing
in tissues [20]. However, the reduction of interaction with
cell-surfaces due to PEG limits its use as a biomaterial for
cell-surface or intracellular drug delivery and targeting.
Therefore, the very property of PEGylation that has made it
clinically useful and commercially successful also limits its
application for drug/nanocarrier targeting to HIV reservoirs
or sanctuary sites such as macrophages, and the central
nervous system [21].
Regardless of this limitation, however, PEG based nano
carriers had been investigated for delivery of antiretroviralto the brain in US. In this study, they developed and evalu-
ated nanocarriers consisting of PEG- or Pluronic-PEI bio-
degradable networks, star PEG-PEI, or PAMAM-PEI-PEG
dendritic networks, as well as nanogels decorated with
multiple ApoE peptide molecules, specifically binding to
the apolipoprotein E receptor. It was shown that there is
efficient uptake of the drugs by monocyte-derived macro-
phages and there was minimal cytotoxicity. The presence
of core-shell and decoration with proteins like brain ApoE
peptide molecules even gives it the highest efficacy against
the virus in the CNS macrophages [22].
Another study done on the application of PEG for de-
livery of antiretroviral drugs also reported the beneficial
effects of this nanopolymer. Accordingly, when PEG of
various length was conjugated with an antithrombin-
binding carrier pentasaccharide (CP) for delivery of
enfuvertide, it shows several fold increase in half life en-
abling weekly dosing of the drugs as well as reducing the
adverse effects associated with the drug. This indicates
that the designed conjugate is a promising compound
with strong potency as a novel long-lasting anti-HIV-1
drug [23].
The recent in vitro study of Sumit and co-workers de-
veloped, evaluated, and compared colloidal gold-loaded,
poly (d,l-lactic-co-glycolic acid)-based nanoparticles con-
taining antiretroviral drug stavudine and uptake of these
nanoparticles by macrophages. It is known that Stavudine
had been one of the first line antiretroviral drugs until the
release of the 2010 ART WHO guideline for adult and
adolescents in resource limited settings. However, the
drug had been out of use in adult people living with HIV
because of serious toxicity associated with it. Now it
seems that there is a hope that this drug may back to the
market as a result of the advent of novel drug delivery
technologies like nanomedicines. In this regard, study in
India found that stavudine was released from polymeric
nanoparticles for a prolonged period (over 63 days) and
up taken by macrophages and hence the promising
opportunity for this drug to enjoy the market again. In
addition to this, even if the finding must be confirmed by
in vivo studies, the fact that this drug could be adminis-
tered in low dose as well as targeted to specific cell in this
study may minimize the systemic toxicity of the drug
several folds [24].
Other potential and fascinating nano polymers for
delivery of antiretroviral drugs are dendrimeres. They
are polymers with large amounts of peripheral groups
and interior cavities making them potential vectors for
chemical drugs, peptides and genes for HIV inhibition.
These materials are capable to either interacting with
the peripheral groups or be encapsulated into the cav-
ities of dendrimers. More surprisingly, many recent
studies showed that these polymers have very good anti-
viral activity themselves against HIV in different animal
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antiretroviral drugs [25-28].
The team of Avrim investigated the role of nano poly-
mers for transdermal delivery of zidovudine which is the
oldest and first line back bone drug in resource limited
settings. They showed that Eudragit RL100 based deliv-
ery of zidovudine achieved the highest in vitro cumula-
tive release profile giving the closest results with the free
drug. This could be attributed to the hydrophilic nature
and swelling of ERL polymer. In contrast, drug release
from hydrophobic Ethyl Cellulose film was slow, as the
polymer was not swellable [29].
In other studies, efavirenz-loaded micelles using sur-
face aptamers to target CD4 cells have been produced in
an oral solution for pediatrics [30,31]. In rats model, the
efavirenz-loaded micellar formulation was compared to
that of a suspension prepared with the content of efa-
virenz capsules in 1.5% carboxymethylcellulose solution
and an EFV solution in a medium-chain triglyceride.
This formulation showed that the encapsulation of efa-
virenz into polymeric micelles of different poly(ethylene
oxide)–poly(propylene oxide) block copolymers signifi-
cantly improves oral bioavailability and reduces the in-
terindividual variability [32].
Monotherapy in HIV/AIDS management is ineffective
and also associated with highest degree of antiretroviral
drug resistance which if develops is difficult to treat. For
this reason treatment of HIV/AIDS today relies on the
combination of at least three drugs from at least two
pharmacologic classes of drugs. There are many studies
done on delivery of single antiretroviral drug using nano
polymers targeting less accessible tissues to free drugs
whereas studies on delivery of several antiretroviral
drugs in a single nano polymer is rare.
The first study which demonstrated the possibility of
nanoparticles [Poly (DL-lactide-co-glycolide) nanoparticles
(PLGA-NPs)] delivery with a combination of three
antiretroviral drugs in single nanoparticle was that of
Destache and co-workers. It was showed that nanoparti-
cles based delivery of single dose of lopinavir/ritonavir and
efavirenz resulted in better and sustained suppression of
the HIV-1 from both serum and tissues (viral reservoirs
and brain) for at least a month compared to free drugs ad-
ministration in mice model. This seems permanent solu-
tion for the high non-adherence rate which in turn lead to
resistant but more difficult to treat virus; hence treatment
failure. The same study showed parenteral delivery of anti-
retroviral drugs is possible and hence overcome the issue
of absorption and metabolism with the resultant improve-
ment in bioavailability these drugs.
This finding created very good opportunity for future
researchers to design delivery of highly active antiretro-
viral therapy using nano-polymers technology which is
very significant breakthrough in HIV/AIDS therapy [33].In another study, nanoparticles for delivery of zidovudine-
lamivudine combination was formulated and characterized
by Sankara V and co-workers. Nanoparticles of AZT-3TC
were prepared through emulsion polymerization in a con-
tinuous aqueous phase of different polymers such as poly
(lactic-co-glycolic acid) PLGA(50:50), poly(lactic acid), and
poly(methyl methacrylate) PMMA, methyl methacrylate-
sulfopropylmethacrylate (MMA-SPM). It was observed
that in vitro drug release was higher from PLGA com-
pared to the other nanoparticles for both drugs. For both
drugs, release from PLGA nanoparticles was greater than
95% within 10 hours and acute toxicity to animal cells was
not detected [34].
Very latest study of Annemarie and co-workers investi-
gated delivery of three antiretrovirals combination in single
nano-polymers similar to the work of Destache and co-
workers. In this work, they developed nanoparticles of bio-
degradable polymer, poly-(dl-lactide-coglycolic acid; PLGA)
containing efavirenz (EFV) and boosted lopinavir (lopina-
vir/ritonavir; LPV/r) by a highpressure homogenization
method. The investigators of this study demonstrated the
significant uptake of the combination of antiretroviral
drugs particles compared to the soluble free antiretroviral
drugs, the subsequent release of levels of antiretroviral
drugs in the nuclear, cytoskeleton, and membrane fractions
of cells with no toxicity for 28 days [35].
Challenges to widely apply nanomedicine for HIV/AIDS
therapy
Even though, nanomedicines are the promising future of
HIV/AIDS prevention and treatment, several hurdles
remain unresolved, including but not limited to toxicity,
unwanted biological interactions and the difficulty and
cost of large-scale synthesis of nanopharmaceuticals
[19]. Another challenge is the fact that targeted delivery
of antiretroviral drugs using nano polymers to viral res-
ervoir sites may lead to HIV drug resistance. This could
be because of two reasons. Firstly, the targeted delivery
of an antiretroviral drugs which if not accompanied by
systemic HAART administration will lead to suboptimal
doses of the drug in non-targeted tissues, with the po-
tential to select out drug resistant mutations there.
Furthermore, most studies involving nanocarriers use a
single antiretroviral drug, which would effectively select
out resistant virus in targeted tissues [29,36]. highlighting
the need to combine at least three drugs for use with nano-
carriers as in conventional HAART in future researches.
Conclusions
In this review, we have gone through many works done
on the application of nano-polymers for the treatment
and prevention of HIV infections. This paper showed
that nanopolymers of different quality are designed and
evaluated for delivery of ARVs. Of all, surprising thing is
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inherent antiviral activity beside their carrier roles which
further makes them more appropriate to use them for
delivery of ARVs in medicine.
In this paper, we have also discovered very promising
features for HIV therapy such as improving residence
time of the drugs at the targeted sites, several fold in-
crease in the uptake of the drugs to those previously less
accessible viral reservoir tissues, improved antiviral effi-
cacy and significantly reduced toxicity of antiretroviral
drugs. Moreover, we have observed that, through appli-
cation of nanomedicines, there will be the possibility of
dosing ARVs every month or more intervals tackling the
current problems of non-adherence related to frequent
and larger dose administration of conventional formula-
tions. Not only these but also there will be possibility of
designing sustained release and controlled release ARV
regimens to be delivered through transdermal, subcuta-
neous and intramuscular routes enabling the drugs to
bypass first pass effect. These findings clearly suggest
the hope that HIV can be completely eradicated from
the body through the application of nano-polymers for
delivery of ARVs in the near future.
However, a lot of assignments left behind for researchers
to overcome the challenges hindering the wider applica-
tion of nanomedicines in treatment of HIV/AIDS. Beside
this, clinical trials involving the use of nano-polymers to
deliver HAART regimens should be designed to investi-
gate both the beneficial and drawbacks of this technology.
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